Skip to main content
Sopharma AD logo

Sopharma AD — Investor Relations & Filings

Ticker · SFA ISIN · BG11SOSOBT18 LEI · 097900BGGW0000048796 BSOBGN Manufacturing
Open in API
Filings indexed 1,482 across all filing types
Latest filing 2023-09-04 Director's Dealing
Country BG Bulgaria
Listing BSOBGN SFA

About Sopharma AD

https://www.sopharmagroup.com/

Sopharma AD is a pharmaceutical company founded in 1933 that specializes in the production, distribution, and export of a wide range of medical products. The company's portfolio includes prescription (Rx) and over-the-counter (OTC) medicines, encompassing both branded and generic drugs. A key area of focus is its traditional plant-based products. Sopharma develops treatments for various conditions, including liver disease, pain management, and smoking cessation. Operating from EU-GMP certified facilities, the company also provides contract manufacturing services and has an established presence in over 40 international markets.

Recent filings

Filing Released Lang Actions
Notification from Aleksandar Tchaoushev under Art. 19 of Regulation (EU) No 596/2014 of 1 September 2023.
Director's Dealing Classification · 100% confidence The document text explicitly contains the heading "NOTIFICATION OF INSIDERS' TRANSACTIONS under art. 19 of Regulation 596/2014". It details transactions made by a person discharging managerial responsibilities (Aleksandar Tchaoushev, a member of the Board of directors) concerning the issuer's financial instruments (Warrants). This content directly corresponds to the definition of Director's Dealing (insider trades by directors/executives). The filing type code for Director's Dealing is DIRS.
2023-09-04 English
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of 1 September 2023.
Director's Dealing Classification · 100% confidence The document text details a transaction involving a 'person discharging managerial responsibilities' (Ognian Donev, Executive director and chairman of the Board of directors of Sopharma AD) regarding the 'Sell' of financial instruments (Warrants). This structure, focusing on insider transactions by management, directly corresponds to the definition of Director's Dealing reports, which track personal share transactions by company directors and executives.
2023-09-04 English
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of 1 September 2023.
Director's Dealing Classification · 100% confidence The document text details a notification concerning a transaction involving a person discharging managerial responsibilities (Ognian Donev, Executive director and chairman of the Board of directors of Sopharma AD). It specifies the person's name, position, the issuer's name, and details of the financial instrument (Shares, ISIN № BG11SOSOBT18). This structure is characteristic of insider trading reports or director's dealing disclosures, which report personal share transactions by company directors and executives. This aligns directly with the definition for Director's Dealing (DIRS).
2023-09-04 English
Notification according to Art. 89t of the LPOS concerning an increase of the capital of "SOFARMA" AD, UIC 831902088, with registered office and management address in the city of Sofia, Nadezhda dis...
Share Issue/Capital Change Classification · 99% confidence The document is a formal 'NOTIFICATION' from 'Sopharma' AD detailing a procedure for a capital increase through the exercise of warrants. It specifies the number of shares, the issue price, the role of the investment intermediary, the subscription terms, and the process for registration and trading. This content directly relates to changes in the company's capital structure and fundraising activities, which aligns precisely with the definition of 'Capital/Financing Update'. The document length (9761 chars) is substantial, indicating it is the primary disclosure, not just an announcement of a report (RPA/RNS).
2023-08-30 English
Consolidated financial report according to IFRS as at 30 June 2023
Regulatory Filings Classification · 19% confidence
2023-08-29 Polish
Completion of the infusion conversion procedure of "Biopharm Engineering" AD
Regulatory Filings Classification · 99% confidence The document is a 'Current report №94/2023' announcing a corporate action: the merger of 'Biopharm Engineering' AD into 'Sopharma' AD, which has been officially registered. This action involves a change in the company's structure and assets, fitting the description of a significant corporate event. While it is a notification, it is not a standard regulatory filing like 10-K or ER. It is a specific announcement regarding a corporate restructuring/merger. Given the options, 'M&A Activity (TAR)' is the closest fit for a merger notification, although 'Regulatory Filings (RNS)' could also apply if TAR is too specific. However, since a merger is explicitly described, TAR is the most precise classification.
2023-08-23 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.